Omeros Form 4: Demopulos receives annual 15k option grant

Rhea-AI Filing Summary

Omeros Corporation (OMER) – Form 4 filing dated 07/01/2025

Non-employee director Dr. Peter A. Demopulos was automatically granted a stock option for 15,000 common shares under the company’s director compensation policy following the annual shareholder meeting on 06/27/2025. The option’s key terms are:

• Exercise price: $3.20 per share
• Expiration: 06/27/2035 (10-year tenor)
• Vesting: fully vests the day before the 2026 annual meeting, contingent on continued board service
• Ownership designation: direct (D); post-grant derivative holdings reported at 15,000 options

The filing reflects routine annual equity compensation for board members and does not disclose any open-market purchases or sales of common shares.

Insights

Corporate Governance Analyst

TL;DR: Routine director option grant; aligns incentives but immaterial to valuation.

The automatic issuance of 15,000 options at $3.20 to Dr. Demopulos is standard practice under Omeros’ director pay program. At today’s share price, the notional value is modest and does not alter control dynamics or ownership concentration. Such equity grants are intended to maintain director–shareholder alignment and are viewed positively from a governance perspective, yet the scale is far too small to influence financial metrics or liquidity. No buying or selling of common stock occurred, so market impact should be negligible.

Portfolio Manager

TL;DR: Neutral event; no immediate trading signal.

A 15k-unit option grant with a 10-year life is commonplace and represents less than 0.03 % of shares outstanding. Because it vests in 12 months, it does not pose near-term dilution risk. I view the disclosure as housekeeping—useful for tracking insider incentives but not for portfolio action. Impact on earnings, cash flow, and strategic outlook is nil; therefore, I assign a neutral rating.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Demopulos Peter A MD

(Last) (First) (Middle)

201 ELLIOTT AVENUE WEST

(Street)

SEATTLE WA 98119

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OMEROS CORP [ OMER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)(1)	$3.2	06/27/2025		A		15,000		(2)	06/27/2035	Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 27, 2025.

2. This option will fully vest and become exercisable on the day before the date of the 2026 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date.

	/s/ Peter B. Cancelmo, Attorney-in-Fact	07/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did OMER director Peter Demopulos receive?

15,000 stock options were granted on 06/27/2025.

What is the exercise price of the newly granted OMER options?

The options carry an exercise price of $3.20 per share.

When will the Demopulos options fully vest?

They will fully vest the day before the 2026 annual shareholder meeting, assuming continued board service.

When do these OMER stock options expire?

The options expire on 06/27/2035, ten years from the grant date.

Did the Form 4 report any open-market purchases or sales of OMER stock?

No. The filing only reports the routine option grant; no shares were bought or sold.